From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes the company recently crossing from being a candidate to being an approved/specified/listed/etc. inside buyers' systems, such that future business can arrive without discrete selling, and that this is new enough that most volume is ahead. Looking at the transcript: The company acquired an agency platform. They talk about being a top 10 Fannie Mae DUS lender, number one small balance lender for Freddie Mac, etc. But that's about their market position, not about being newly inserted into a buyer's system. They mention "dominance in the small balance loan market" but that's not a gateway. They also talk about growing their servicing portfolio, but that's not about being approved. They mention "we are also extremely positive on outlook for 2017 and believe that the significant amount of commercial real-estate debt that is maturing combined with our strong brand and dominance in the small balance loan market we could exceed our 2016 record origination numbers in 2017." That's just market opportunity. No mention of being added to a preferred supplier list, procurement program, formulary, etc. The agency platform is a business they acquired, but that's not about being newly approved. They were already a lender. The acquisition gave them a platform, but they were already in the market. The question asks: "does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results?" The transcript does not contain such a description. They talk about being a top lender, but that's not about being inserted into a system. They talk about growth, but not about a new gateway. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.